AU2002314780A1 - Agents that regulate apoptosis - Google Patents

Agents that regulate apoptosis

Info

Publication number
AU2002314780A1
AU2002314780A1 AU2002314780A AU2002314780A AU2002314780A1 AU 2002314780 A1 AU2002314780 A1 AU 2002314780A1 AU 2002314780 A AU2002314780 A AU 2002314780A AU 2002314780 A AU2002314780 A AU 2002314780A AU 2002314780 A1 AU2002314780 A1 AU 2002314780A1
Authority
AU
Australia
Prior art keywords
agents
regulate apoptosis
apoptosis
regulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002314780A
Other languages
English (en)
Inventor
Jack Barber
Cellia Habita
Benjamin Keily
Joan Robbins
Richard Tritz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusol Inc
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of AU2002314780A1 publication Critical patent/AU2002314780A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2002314780A 2001-05-14 2002-05-14 Agents that regulate apoptosis Abandoned AU2002314780A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29092701P 2001-05-14 2001-05-14
US60/290,927 2001-05-14
PCT/US2002/015198 WO2002092840A2 (en) 2001-05-14 2002-05-14 Agents that regulate apoptosis

Publications (1)

Publication Number Publication Date
AU2002314780A1 true AU2002314780A1 (en) 2002-11-25

Family

ID=23118085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002314780A Abandoned AU2002314780A1 (en) 2001-05-14 2002-05-14 Agents that regulate apoptosis

Country Status (6)

Country Link
US (1) US20040248830A1 (enExample)
EP (1) EP1474175A4 (enExample)
JP (1) JP2005501524A (enExample)
AU (1) AU2002314780A1 (enExample)
CA (1) CA2446991A1 (enExample)
WO (1) WO2002092840A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677739A4 (en) * 2003-09-04 2008-07-23 Immusol Inc METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS
US8012948B2 (en) * 2008-10-15 2011-09-06 Promising Future, Llc Fas/FasL or other death receptor targeted methods and compositions for killing tumor cells
WO2011129371A1 (ja) * 2010-04-14 2011-10-20 国立大学法人鳥取大学 ５－ＦＵ単独及びＩＦＮ－α／５－ＦＵ併用時の抗腫瘍効果を増強する遺伝子群

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996741A4 (en) * 1997-01-23 2004-06-09 Immusol Inc FUNCTIONAL ANALYSIS AND GENE DISCOVERY USING TARGET SPECIFIC RIBOZY VECTOR BANKS OR WELL MADE RANDOM

Also Published As

Publication number Publication date
US20040248830A1 (en) 2004-12-09
CA2446991A1 (en) 2002-11-21
EP1474175A2 (en) 2004-11-10
EP1474175A4 (en) 2005-01-19
WO2002092840A3 (en) 2004-09-10
WO2002092840A2 (en) 2002-11-21
JP2005501524A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002313565A1 (en) Putter-heads
AU2002300754A1 (en) New Combination
AU2002251024A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AU2002321215A1 (en) Substituted 4-aminocyclohexanols
AU2002364901A1 (en) Object decontaminator
EP1283298B8 (en) Refiner
AU2002314780A1 (en) Agents that regulate apoptosis
AU2002367429A1 (en) Apoptosis inductor
AU2002361985A1 (en) Microemulsifier
AU2002313943A1 (en) Electromobile
GB0123025D0 (en) Apoptosis
AU2002226571A1 (en) Biligands
AU2002245337A1 (en) Epoxyvibsanin b
AU2002329420A1 (en) Apoptosis
AU2002342625A1 (en) Methylene-4-azasteroids
AU2002353664A1 (en) Routeplanner
AU2002311644A1 (en) Apoptosis inducer
AU2002344495A1 (en) Anticaner agents
AU2002258599A1 (en) Anti-psychosis combination
AUPR473201A0 (en) Direct reduction
AU2002358003A1 (en) Substituted acylaminophenyluracils
AU2002317861A1 (en) Substituted benzo-nitro-heterocycles
AU2001274055A1 (en) Head-drum scraper
AU2002257517A1 (en) Scraper

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase